Cardiovascular disease has become a serious public health problem with the increasing degree of aging in China. Anticoagulants are essential to prevent thrombosis and reduce the risk of stroke. Rivaroxaban has occupied a certain share of the Chinese market as an oral anticoagulant.

Rivaroxaban is an oral anticoagulant and an oral anticoagulant drug that directly inhibits thrombin. It is often used to prevent thrombosis and reduce the risk of stroke. It can prevent the generation of thrombin in the blood, thereby reducing the formation of thrombus and reducing the risk of thrombosis-related diseases. Rivaroxaban is commonly used to treat conditions such as venous thrombosis, pulmonary embolism, atrial fibrillation, and artificial heart valve replacement surgery.